RT Journal Article
SR Electronic
T1 Evaluation of patient-specific cell free DNA assays for monitoring of minimal residual disease in solid tumors
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.04.07.22273446
DO 10.1101/2022.04.07.22273446
A1 Dadasaheb Akolkar
A1 Darshana Patil
A1 Sneha Puranik
A1 Swapnil Puranik
A1 Pratiksha Sunil Nandre
A1 Karishma Raosaheb Sabale
A1 Sachin Apurwa
A1 Harshal Bodke
A1 Navin Shrivastava
A1 Vineet Datta
A1 Stefan Schuster
A1 Jinumary John
A1 Ajay Srinivasan
A1 Rajan Datar
YR 2022
UL http://medrxiv.org/content/early/2022/04/12/2022.04.07.22273446.abstract
AB Real time monitoring of disease status is an essential part of cancer management. The low sensitivity and specificity of serum markers and the constraints and risks associated with radiological scans prompt the need for accurate non-invasive means to monitor minimal residual disease (MRD) in solid tumors. In this study we describe MRD evaluation via profiling of patient-specific gene variants in cell free tumor DNA (i.e., ctMRD). We evaluate the feasibility of this approach for real time monitoring of tumor load dynamics in response to anticancer treatments. We prioritized 162 hot spot mutations for designing ctMRD assays based on literature review. These ctMRD assays were evaluated in 436 plasma specimens with a median of 6 (range 3-18) longitudinal evaluations in a cohort of 48 patients with various solid tumors. In patients with partial radiological response (PR), Mutant Allele Fraction (MAF) showed high correlation (84%) with radiological response and tumor volume (cm3) compared to conventional CA markers (53%). Total plasma ctDNA level was significantly higher in patients with 2-5 metastatic sites compared with single metastatic site (P = 0.04) and discriminated patients with stable disease (SD) and progressive disease (PD) from patients with partial response (PR) (P =0.01 and P = 0.04, respectively). Collectively, the present study shows that changes in mutation burden evaluated using patient specific ctMRD assays is a highly sensitive approach for monitoring of therapy response.Competing Interest StatementAll authors are employees of Datar Cancer Genetics, India which offers commercial services in the area of onco-diagnosis and therapy management.Clinical TrialCTRI/2018/02/011808Funding StatementNo external funding was received for the present study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Ethics Committees of both the participating institutions - Datar Cancer Genetics and HCG Manavata Cancer Centre. All patients provided written informed consent. The study was performed in accordance with the Declaration of Helsinki.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe minimal data set underlying the results described in the manuscript are within the manuscript and its Supporting Information file.